Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients
NCT04753203
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
65
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Colorectal Cancer
PIK3CA Gene Mutation
Interventions
DRUG:
Alpelisib plus Capecitabine combination
Sponsor
Korean Cancer Study Group